ArticleAntimicrobial agents and chemotherapy2015
Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Ligand decorated nanostructure carrier systems for targeted delivery of antimalarials.Discover nano · 2026Review
- Clinically applicable parasite viability assay for rapid assessment of antimalarial pharmacodynamic endpoints.Antimicrobial agents and chemotherapy · 2025Article
- An artesunate pharmacometric model to explain therapeutic responses in falciparum malaria.The Journal of antimicrobial chemotherapy · 2023Article
- Article
- Artemisinin resistance and malaria elimination: Where are we now?Frontiers in pharmacology · 2022Review
- Efficient Treatment of Experimental Cerebral Malaria by an Artemisone-SMEDDS System: Impact of Application Route and Dosing Frequency.Antimicrobial agents and chemotherapy · 2021Article
- Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges.BioMed research international · 2021Review
- Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic MarkersAntimicrobial agents and chemotherapy · 2019Article
- Optimal Treatments for Severe Malaria and the Threat Posed by Artemisinin Resistance.The Journal of infectious diseases · 2019Article
- Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia.The AAPS journal · 2017Article
- Split dosing of artemisinins does not improve antimalarial therapeutic efficacy.Scientific reports · 2017Article
- Combating multidrug-resistant Plasmodium falciparum malaria.The FEBS journal · 2017Review
- Impact of Extended Duration of Artesunate Treatment on Parasitological Outcome in a Cytocidal Murine Malaria Model.Antimicrobial agents and chemotherapy · 2017Article
- Mathematical Modelling to Guide Drug Development for Malaria Elimination.Trends in parasitology · 2017Review
- Malaria parasite clearance.Malaria journal · 2017Review
- Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence.BMJ global health · 2017Article
- Quantifying the pharmacology of antimalarial drug combination therapy.Scientific reports · 2016Article
- OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens.Malaria journal · 2016Article
- Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.PloS one · 2016Article
- How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
There is considerable concern that malaria parasites are starting to evolve resistance to the current generation of antimalarial drugs, the artemisinin-based combination therapies (ACTs). We use pharmacological modeling to investigate changes in ACT effectiveness likely to occur if current regimens are extended from 3 to 5 days or, alternatively, given twice daily over 3 days. We show that the pharmacology of artemisinins allows both regimen changes to substantially increase the artemisinin killing rate. Malaria patients rarely contain more than 10(12) parasites, while the standard dosing regimens allow approximately 1 in 10(10) parasites to survive artemisinin treatment. Parasite survival falls dramatically, to around 1 in 10(17) parasites if the dose is extended or split; theoretically, this increase in drug killing appears to be more than sufficient to restore failing ACT efficacy. One of the most widely used dosing regimens, artemether-lumefantrine, already successfully employs a twice-daily dosing regimen, and we argue that twice-daily dosing should be incorporated into all ACT regimen design considerations as a simple and effective way of ensuring the continued long-term effectiveness of ACTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.